E-LIB Suche - Ergebnisse für: Paracha, N

1

EE519 Do We Need Three-State Decision Analytic Models in Me..:

Felizzi, F. ; Paracha, N.
Value in Health. 26 (2023) 12 - p. S151 , 2023

Link: https://doi.org/10.1016/..

2

SA41 Novel Method for Indirect Comparison of Treatment Sequ..:

Aceituno, D. ; Grossman, J. ; Paracha, N...
Value in Health. 26 (2023) 12 - p. S549 , 2023

Link: https://doi.org/10.1016/..

3

P50 Joint Modelling of Intermediate Longitudinal Biomarkers..:

Linsell, L. ; Paracha, N. ; Grossman, J....
Value in Health. 26 (2023) 12 - p. S12-S13 , 2023

Link: https://doi.org/10.1016/..

4

P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility..:

Felizzi, F ; Upton, A ; Paracha, N
Value in Health. 25 (2022) 1 - p. S11 , 2022

Link: https://doi.org/10.1016/..

5

PRO93 DO CAREGIVERS AND PATIENTS VALUE THE AVOIDANCE OF LUM..:

Lo, S.H. ; Paracha, N. ; Gorni, K..
Value in Health. 23 (2020) - p. S346 , 2020

Link: https://doi.org/10.1016/..

6

PRO92 ESTIMATING DISUTILITIES IN SPINAL MUSCULAR ATROPHY US..:

Lo, S.H. ; Paracha, N. ; Ali, S..
Value in Health. 23 (2020) - p. S345 , 2020

Link: https://doi.org/10.1016/..

7

PCN104 Cost-Utility MODEL of Trastuzumab Emtansine (T-DM1) ..:

Akyol Ersoy, B. ; Erdogan-Ciftci, E. ; Yanik, L....
Value in Health. 23 (2020) - p. S441 , 2020

Link: https://doi.org/10.1016/..

8

PRO47 SURVIVAL ESTIMATES FOR TYPE 2 SPINAL MUSCULAR ATROPHY:

Paracha, N. ; Gorni, K. ; Mitchell, S..
Value in Health. 23 (2020) - p. S337 , 2020

Link: https://doi.org/10.1016/..

9

PRO62 SPINAL MUSCULAR ATROPHY: DEVELOPMENT OF NATURAL HISTO..:

Paracha, N. ; Gorni, K. ; Hudson, P.
Value in Health. 23 (2020) - p. S339 , 2020

Link: https://doi.org/10.1016/..

10

PCN76 A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB FOR PRE..:

Pinheiro, B. ; Silva Miguel, L. ; Alarcão, J....
Value in Health. 22 (2019) - p. S450 , 2019

Link: https://doi.org/10.1016/..

11

PNS51 SHIFTING THE MARKET ACCESS FRAMEWORK TO INVESTMENT DE..:

Felizzi, F. ; Thuresson, P.O. ; Paracha, N.
Value in Health. 22 (2019) - p. S770-S771 , 2019

Link: https://doi.org/10.1016/..

12

PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION..:

Felizzi, F ; Bennett, I ; Pletscher, M...
Value in Health. 21 (2018) - p. S382-S383 , 2018

Link: https://doi.org/10.1016/..

13

PCN176 - A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERS..:

Moeremans, K. ; Van Bellinghen, L. ; De Celle, T...
Value in Health. 21 (2018) - p. S44 , 2018

Link: https://doi.org/10.1016/..

14

Evaluating The Clinical Effectiveness of Trastuzumab Emtans..:

Paracha, N ; Irahara, N ; Schuhmacher, C
Value in Health. 20 (2017) 9 - p. A416 , 2017

Link: https://doi.org/10.1016/..

15

Rate of Hospitalization Due To Adverse Event and Length of ..:

Paracha, N ; Felizzi, F
Value in Health. 20 (2017) 9 - p. A447 , 2017

Link: https://doi.org/10.1016/..